Showing 4721-4730 of 7586 results for "".
- Valeant Enters Fulfillment Agreements With Walgreenshttps://practicaldermatology.com/news/valeant-enters-fulfillment-agreements-with-walgreens/2458783/Valeant Pharmaceuticals International, Inc. entered into new fulfillment agreements with Walgreens and indicated that it intends to extend this distribution model to additional participating independent retail pharmacies. In conjunction with the fulfillment agreement, Valeant says it will reduce
- Aclaris Therapeutics, Inc. Appoints Brett Fair as Senior Vice President of Commercial Operationshttps://practicaldermatology.com/news/aclaris-therapeutics-inc-appoints-brett-fair-as-senior-vice-president-of-commercial-operations/2458784/Aclaris Therapeutics, Inc. has appointed Brett Fair as Senior Vice President of Commercial Operations. Mr. Fair brings more than 18 years of pharmaceutical commercialization and business
- Galderma and ZELTIQ Announce US Collaboration in Aestheticshttps://practicaldermatology.com/news/galderma-and-zeltiq-announce-us-collaboration-in-aesthetics/2458785/Galderma and ZELTIQ Aesthetics, Inc. entered into a new collaboration across the companies’ innovative aesthetic brands and offerings. Effective immediately, the creation of this nationwide collaboration will provide healthcare professionals and consumers with greater access to a robust ran
- Valeant Offers Comment on Fake Twitter Accounthttps://practicaldermatology.com/news/valeant-offers-comment-on-fake-twitter-account/2458786/Valeant issued the following statement about a fake Twitter account created to impersonate Mike Pearson: We are aware that someone impersonating Mike Pearson has created an account on Twitter, and we have contacted Twitter to report the unauthorized use. Mike Pearson does not
- AAD Issues Statement on Skin Cancer Screeninghttps://practicaldermatology.com/news/aad-issue-statement-on-skin-cancer-screening/2458789/Mark G. Lebwohl, MD, FAAD, President, American Academy of Dermatology issued the following statement on skin cancer screenings: “The American Academy of Dermatology believes that early detection is vital in the fight against skin cancer, the most common cancer in the United States.
- AMA Disappointed CMS Moving Ahead with Problematic Information on Website for Patientshttps://practicaldermatology.com/news/ama-disappointed-cms-moving-ahead-with-problematic-information-on-website-for-patients/2458788/The AMA is "dismayed" that CMS is moving forward with its Physician Compare website, the AMA has issued a statement to express its concern "that incomplete and potentially inaccurate information...will misinform patients." “Given the widespread accuracy issu
- ASDS Awards Inagural Research Grant Recipient of Fredric S. Brandt, MD, Innovations in Aesthetics Fellowshiphttps://practicaldermatology.com/news/asds-awards-inagural-research-grant-recipient-of-fredric-s-brandt-md-innovations-in-aesthetics-fellowship/2458790/Abigail Waldman, MD, of Chicago, has been chosen as the inaugural research grant recipient of the Fredric S. Brandt, MD, Innovations in Aesthetics Fellowship Fund. Dr. Waldman was awarded $41,500 for her research project entitled “Patient Motivations and Preferences Regarding the De
- Review Does Not Support Monthly Lab Testing for Oral Isotretinoin Use for Acnehttps://practicaldermatology.com/news/review-does-not-support-monthly-lab-testing-for-oral-isotretinoin-use-for-acne/2458793/A review of medical literature does not support monthly laboratory testing for all patients who are using standard doses of the acne medication isotretinoin, according to an article published online by JAMA Dermatology</
- Rock Creek Pharmaceuticals Adds KOLs to Enhance Dermatological Disease Programhttps://practicaldermatology.com/news/rock-creek-pharmaceuticals-adds-kols-to-enhance-dermatological-disease-program/2458794/Rock Creek Pharmaceuticals, Inc., a clinical stage drug development company focused on the application of its lead compound being developed to treat chronic inflammatory conditions, has retained two Key Opinion Leaders (KOLs), each having renowned international expertise in dermatological d
- Aqua Pharmaceuticals Acquires US Rights to Veltin Gel and Altabax Ointmenthttps://practicaldermatology.com/news/aqua-pharmaceuticals-acquires-us-rights-to-veltin-gel-and-altabax-ointment/2458795/Aqua Pharmaceuticals, LLC acquired the US rights to two dermatology products— Veltin (clindamycin phosphate and tretinoin) Gel 1.2%/0.025% and Altabax (retapamulin) Ointment 1%, after Almirall, parent company of Aqua, acquired the rights to the products from GlaxoSmithKline. Both Veltin and